Indianapolis, IN, United States of America

Marshall A Skelton


Average Co-Inventor Count = 11.2

ph-index = 4

Forward Citations = 51(Granted Patents)


Company Filing History:


Years Active: 1997-2002

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Mind of Marshall A. Skelton

Introduction: Marshall A. Skelton is a prominent inventor based in Indianapolis, IN, known for his contributions to the field of pharmacology. With a total of six patents to his name, Skelton has made significant strides in the development of compounds that inhibit platelet aggregation, showcasing his expertise and creativity as an inventor.

Latest Patents: Skelton's latest innovations include two related patents focusing on glycoprotein IIb/IIIa antagonists. The first patent details certain bicyclic compounds characterized by a nucleus formed from two fused six-membered rings, such as isoquinoline or tetrahydronaphthalene. These compounds are substituted with both basic and acidic functionalities, rendering them valuable for inhibiting platelet aggregation. Similarly, the second patent expands on this concept, presenting compounds that utilize a different bicyclic structure, including benzopyran and other fused ring systems, maintaining their utility in the same therapeutic area.

Career Highlights: Currently, Marshall Skelton is an integral part of Eli Lilly and Company, where he applies his expertise in pharmaceuticals to develop innovative solutions for medical challenges. His work has a substantial impact on advancing medical treatments and improving patient outcomes.

Collaborations: Throughout his career, Skelton has collaborated with talented coworkers such as Matthew Joseph Fisher and Anne Marie Happ. These collaborations have fostered a dynamic environment of creativity and innovation, contributing to the development of cutting-edge biopharmaceutical products.

Conclusion: Marshall A. Skelton exemplifies the spirit of innovation in the pharmaceutical industry. With his pivotal contributions in glycoprotein antagonists, he is making a notable impact that could shape future treatments for various conditions. His work at Eli Lilly and Company, alongside skilled colleagues, highlights the importance of collaboration in driving innovation forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…